Published in Obesity and Diabetes Week, December 12th, 2005
The trial evaluated rimonabant in overweight or obese patients with abnormal blood lipids (high triglycerides and/or high total cholesterol/HDL-cholesterol ratios) . Improvements included a reduction in triglyceride levels and increases in HDL-cholesterol (good cholesterol).
There were also reductions in waist circumference and body...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.